Otsuka : Pharmaceutical Completes Acquisition of Visterra (84KB)
September 02, 2018 at 07:42 pm EDT
Share
September 3, 2018
FOR IMMEDIATE RELEASE
Company name:
Otsuka Holdings Co., Ltd.
Representative name:
Tatsuo Higuchi
President and Representative Director, CEO
Stock ticker:
4578, Tokyo Stock Exchange, First Section
Contact:
Yuji Kogure
Director, Investor Relations Department
Telephone: +81-3-6361-7411
Otsuka Pharmaceutical Completes Acquisition of Visterra
Otsuka Pharmaceutical Co., Ltd. (Otsuka), a wholly owned subsidiary of Otsuka Holdings Co., Ltd., completed its acquisition* of Visterra, Inc. (Visterra) on August 31, 2018, following the fulfillment of completion requirements including expiration or termination of the waiting period under U.S. antitrust laws and the completion of required legal procedures for the transaction.
Upon the completion of the acquisition, Visterra became a wholly owned subsidiary of Otsuka America, Inc., which is a U.S. holding company and a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. of Japan.
*The agreement for the acquisition was announced on July 11, 2018"Otsuka Pharmaceutical to Acquire Visterra"
The impact of this acquisition on the current year's operational results will be announced upon finalization of accounting treatment.
1
Attachments
Original document
Permalink
Disclaimer
Otsuka Holdings Co. Ltd. published this content on 03 September 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 September 2018 23:41:01 UTC
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
